UNSPSC 51294502: Altanserin

This classification denotes a serotonin antagonist with the molecular formula C22H22FN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5015H744JQ chemically known as 3-(2-(4-(p-fluorobenzoyl)piperidino)ethyl)-2-thio-2,4(1h,3h)-quinazolinedione but generally known as altanserin, which bears US NIH Compound Identifier 3033677. European Medicines Agency schedules Altanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05375MIG.

UNSPSC 51294502 Altanserin, a Commodity code, does not reflect the actual recent state and local procurement activity tagged under it. The source shows three recent opportunities—naloxone and drug deactivation systems procurement, a pharmacy benefit program RFI, and a multistate generic pharmaceuticals cooperative purchasing agreement—none of which involve altanserin, a selective serotonin 5-HT1A receptor antagonist with no presence in the recent solicitations. The code shows little relevant recent activity; the mismatch between the nominal code definition and the work actually being bought suggests either miscategorization in the source data or minimal state and local demand for altanserin specifically.

The three posted opportunities span health system acquisitions and pharmacy benefit program development across Florida, Texas, and a multistate cooperative (Minnesota, Oregon, and other participating jurisdictions), but altanserin does not appear in any scope of work. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and safe drug deactivation systems; the Texas Health and Human Services Commission issued an RFI (HHS0017013, closed April 3, 2026) to explore direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local health facilities. None of these solicitations target altanserin or reference the code's nominal scope. Business development professionals should verify whether procurement under this code actually exists in their target markets before investing sourcing effort.